KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.88
+5.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.74
From 52W high−82.38%
Volume1.63M
Market cap$42.64M
P/E (TTM)—
P/S (TTM)0.3x
Div yield—
Key dataSep 18, 2026
Open
$1.74
From 52W high
−82.38%
Volume
1.63M
Market cap
$42.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
34.1
MomentumView details →
1D Return
+5.03%
YTD Return
−75.82%
SummaryUpdated Jun 1, 2026
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage pharmaceutical company founded in 2008 and headquartered in Newton, Massachusetts. The company went public in 2013 and specializes in developing and commercializing a novel class of cancer drugs called Selective Inhibitor of Nuclear Export (SINE) compounds. Karyopharm's lead product, XPOVIO (selinexor), is currently approved for multiple myeloma and diffuse large B-cell lymphoma, with the company advancing an ambitious pipeline of three Phase 3 trials targeting additional cancer indications including myelofibrosis and endometrial cancer.
Similar companies
Latest newsMore news →
Karyopharm Therapeutics submitted a supplemental New Drug Application to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis.20d agoKaryopharm Therapeutics reported a Q2 2026 loss of $2.32 per share, missing the Zacks Consensus Estimate of a loss of $1.53, and compared to a loss of $4.32 per share a year ago.38d ago